Literature DB >> 26226643

Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?

J Daniel Hothersall1, Alastair J Brown2, Ian Dale3, Philip Rawlins4.   

Abstract

Residence time describes the how long a ligand is bound to its target, and is attracting interest in drug discovery as a potential means of improving clinical efficacy by increasing target coverage. This concept, as originally applied to antagonists, is more complicated for G-protein-coupled receptor (GPCR) agonists because of the transiency of receptor responses (via desensitization and internalization). However, in some cases sustained GPCR agonist responses have been observed, with evidence consistent with a role for slow binding kinetics. We propose a model to explain our understanding of how residence time and rebinding might influence sustained signaling by internalized receptors. We also highlight the anticipated benefit for drug discovery of fully understanding and exploiting these phenomena to target desirable receptor response profiles selectively.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26226643     DOI: 10.1016/j.drudis.2015.07.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  21 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  When trafficking and signaling mix: How subcellular location shapes G protein-coupled receptor activation of heterotrimeric G proteins.

Authors:  Braden T Lobingier; Mark von Zastrow
Journal:  Traffic       Date:  2019-02       Impact factor: 6.215

Review 3.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

4.  The Added Value of Assessing Ligand-Receptor Binding Kinetics in Drug Discovery.

Authors:  Dong Guo; Laura H Heitman; Adriaan P IJzerman
Journal:  ACS Med Chem Lett       Date:  2016-08-19       Impact factor: 4.345

5.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

6.  Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics.

Authors:  Giuseppe Deganutti; Andrei Zhukov; Francesca Deflorian; Stephanie Federico; Giampiero Spalluto; Robert M Cooke; Stefano Moro; Jonathan S Mason; Andrea Bortolato
Journal:  In Silico Pharmacol       Date:  2017-11-20

Review 7.  Fluorescent ligands: Bringing light to emerging GPCR paradigms.

Authors:  Mark Soave; Stephen J Briddon; Stephen J Hill; Leigh A Stoddart
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

Review 8.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

9.  Picomolar Affinity Antagonist and Sustained Signaling Agonist Peptide Ligands for the Adrenomedullin and Calcitonin Gene-Related Peptide Receptors.

Authors:  Jason M Booe; Margaret L Warner; Augen A Pioszak
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-24

Review 10.  Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.

Authors:  Abigail C Cornwell; Michael E Feigin
Journal:  Trends Pharmacol Sci       Date:  2020-10-22       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.